Welcome to our dedicated page for Grifols SEC filings (Ticker: GIFLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Grifols, S.A. filings document the formal U.S. reporting record of a Spanish foreign private issuer in plasma-derived medicines. Its 6-K reports include quarterly results releases, earnings presentations, consolidated and individual audited financial statements, and directors' responsibility statements covering financial position, business results, and principal risks and uncertainties.
The filings also disclose Biopharma performance, immunoglobulin, albumin, Alpha-1 and Specialty Proteins trends, regulatory approvals for plasma-related products, and capital-structure actions such as term-loan and revolving-credit refinancing. Inside-information and other-relevant-information notices cover governance, financing, liquidity, leverage, and corporate-structure matters.
Permian Investment Partners and affiliated funds reported beneficial ownership of 18,607,262 Grifols Class B shares, equal to 7.1% of the class. The holdings are spread across several Permian funds and managed accounts, including ADRs and ordinary shares.
The ownership percentages are based on 261,425,110 Class B shares outstanding as of December 31, 2024, as disclosed in Grifols’ Form 20-F. The filers certify the securities were not acquired to change or influence control of Grifols.
Permian Investment Partners and affiliated funds reported beneficial ownership of 18,607,262 Grifols Class B shares, equal to 7.1% of the class. The holdings are spread across several Permian funds and managed accounts, including ADRs and ordinary shares.
The ownership percentages are based on 261,425,110 Class B shares outstanding as of December 31, 2024, as disclosed in Grifols’ Form 20-F. The filers certify the securities were not acquired to change or influence control of Grifols.
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a significant passive ownership position in Grifols SA common shares. The investment adviser reports beneficial ownership of 20.67% of the class, indicating it controls a large block of the company’s equity.
Brandes reports no sole voting or dispositive power over these shares and instead lists only shared dispositive power, meaning decisions to sell or otherwise dispose are made in a shared capacity. The filing also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Grifols.
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a significant passive ownership position in Grifols SA common shares. The investment adviser reports beneficial ownership of 20.67% of the class, indicating it controls a large block of the company’s equity.
Brandes reports no sole voting or dispositive power over these shares and instead lists only shared dispositive power, meaning decisions to sell or otherwise dispose are made in a shared capacity. The filing also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Grifols.
Grifols, S.A. reports a change in its Board support roles. The Board of Directors unanimously approved, with effect from 1 January 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés. At the same time, Mrs. Núria Martín Barnés has been appointed as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán. The decision followed a favourable report from the Appointments and Remuneration Committee.
Grifols, S.A. reports a change in its Board support roles. The Board of Directors unanimously approved, with effect from 1 January 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés. At the same time, Mrs. Núria Martín Barnés has been appointed as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán. The decision followed a favourable report from the Appointments and Remuneration Committee.
Grifols, S.A. reports that the European Medicines Agency (EMA) has issued a Certificate of Compliance with Community legislation for plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), the joint venture created in 2020 with Egypt’s National Service Projects Organization. This certification follows EMA inspection of GEPD’s plasma centers and verification that donor selection, plasma collection, quality controls, and storage meet European quality and safety standards.
The EMA certification allows GEPD not only to manufacture plasma-derived products but also to commercialize them throughout Europe and in countries that follow EMA legislation. Grifols describes this as a huge milestone, noting it is the first plasma company to achieve this step for Egyptian plasma, and that it positions Egypt as the first country in Africa and the Middle East with a fully integrated plasma collection and processing system meeting these strict international standards.
Brandes Investment Partners, L.P. filed an amended Schedule 13G reporting beneficial ownership in Grifols SA. As of 09/30/2025, Brandes reports beneficial ownership of 29,126,291.55 ADRs, representing 19.6% of the class.
The filer reports no sole or shared voting power and shared dispositive power over 29,126,291.55 ADRs. Item 4 also notes holdings of 22,107,370 ordinary shares and 29,126,291.55 ADRs for which dispositive power is shared. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Brandes Investment Partners, L.P. filed an amended Schedule 13G reporting beneficial ownership in Grifols SA. As of 09/30/2025, Brandes reports beneficial ownership of 29,126,291.55 ADRs, representing 19.6% of the class.
The filer reports no sole or shared voting power and shared dispositive power over 29,126,291.55 ADRs. Item 4 also notes holdings of 22,107,370 ordinary shares and 29,126,291.55 ADRs for which dispositive power is shared. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Grifols (GRFS) reported Q3 2025 results with revenue of EUR 1,865 million and quarterly group profit of EUR 127 million, reflecting strong momentum in its Value Creation Plan. Year-to-date revenues reached EUR 5,542 million, up 7.7% at constant currency, while adjusted EBITDA was EUR 1,358 million with a 24.5% margin. Q3 adjusted EBITDA was EUR 482 million, up 8.8% at constant currency, with a 25.8% margin.
Year-to-date net profit was EUR 304 million, up 245%. Free cash flow pre-M&A and pre-dividend was EUR 203 million in Q3, bringing the nine-month total to EUR 188 million, a EUR 257 million improvement versus last year. Leverage improved to 4.2x from 5.1x a year ago, and liquidity rose to EUR 1,475 million.
Growth was led by Biopharma, with a 9.1% constant-currency increase year-to-date and 10.9% in Q3. Immunoglobulin revenues rose 14.4% year-to-date, while subcutaneous IG grew more than 60%. Albumin declined 3.9% year-to-date due to pricing adjustments in China. The Diagnostic business generated EUR 479 million year-to-date, up 1.4%, with FDA approval to begin manufacturing Gel Cards and reagent Red Blood Cells in San Diego. Grifols noted potential full-year FX headwinds of approximately EUR 70 million to adjusted EBITDA if current rates persist.
Grifols (GRFS) reported Q3 2025 results with revenue of EUR 1,865 million and quarterly group profit of EUR 127 million, reflecting strong momentum in its Value Creation Plan. Year-to-date revenues reached EUR 5,542 million, up 7.7% at constant currency, while adjusted EBITDA was EUR 1,358 million with a 24.5% margin. Q3 adjusted EBITDA was EUR 482 million, up 8.8% at constant currency, with a 25.8% margin.
Year-to-date net profit was EUR 304 million, up 245%. Free cash flow pre-M&A and pre-dividend was EUR 203 million in Q3, bringing the nine-month total to EUR 188 million, a EUR 257 million improvement versus last year. Leverage improved to 4.2x from 5.1x a year ago, and liquidity rose to EUR 1,475 million.
Growth was led by Biopharma, with a 9.1% constant-currency increase year-to-date and 10.9% in Q3. Immunoglobulin revenues rose 14.4% year-to-date, while subcutaneous IG grew more than 60%. Albumin declined 3.9% year-to-date due to pricing adjustments in China. The Diagnostic business generated EUR 479 million year-to-date, up 1.4%, with FDA approval to begin manufacturing Gel Cards and reagent Red Blood Cells in San Diego. Grifols noted potential full-year FX headwinds of approximately EUR 70 million to adjusted EBITDA if current rates persist.
Grifols, S.A. notified that on September 29, 2025 the Board established a Strategy Committee with an advisory role to assist the Board of Directors and to make proposals on strategic initiatives and developments. The notice states the committee's specific authorities are set out in the Board's Internal Functioning Regulations and the Strategy Committee's own Regulations. The company also amended those Internal Functioning Regulations to formally allocate authorities to the new Strategy Committee. The report is signed by Nuria Martín Barnés as Secretary to the Board and by David I. Bell as Authorized Signatory.